BenevolentAI

Collaboration utilises BenevolentAI’s end-to-end AI platform capabilities to deliver novel drug candidates, initially for three targets in…

Partnerships with BenevolentAI and Exscientia to drive accelerated drug discovery with higher probability of success Access to…

BenevolentAI, a leader in the development of advanced AI that accelerates biopharma discovery, announces that the first participants have been dosed…

BenevolentAI , a leader in the development of cutting-edge AI that accelerates biopharma discovery, announces the successful delivery of its…

BenevolentAI, a leader that combines cutting-edge Artificial Intelligence (AI) and science to accelerate biopharma discovery and development,…

Marketplace and partnership promote information sharing and collaboration across the biopharma industry to accelerate new drug discovery…

BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI) announces top-line results from its Phase IIa, randomised, double-blind,…

The University of Oxford team running the Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial, which recruited over 4,000 patients, have…

- The Benevolent PlatformTM for AI-driven drug discovery identified and validated a novel biological target not previously linked to the disease -…

Recently, a news report suggested that a team of AI scientists have made a belligerent effort to identify hundreds of new drugs as a potential…